Grünenthal acquires Averitas Pharma and establishes commercial footprint in the US

15-Nov-2018 - USA

Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the remaining global rights, including the US rights, for the product from Acorda Therapeutics.

"I am proud to say that we are now establishing our own commercial presence in the world's biggest pharma market, the US, for the first time," says Gabriel Baertschi, Grünenthal's Chief Executive Officer. "This acquisition is another important milestone in executing our growth strategy and expanding our business across multiple pain related therapeutic categories and geographies. Averitas Pharma is a perfect match due to its significant specialty pharma expertise in the US market and experience in different commercial models also beyond the typical 'reach and frequency' approach".

Averitas Pharma will be enhancing the commercial distribution model for Qutenza® towards a specialty pharmacy and hub services model that makes it easier for patients to access the product and support health care professionals in prescribing and applying it. "This will help us transitioning and ramping up the Qutenza® US business, bringing the product back on the growth path in the US," explains Gabriel Baertschi.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Living Cell Technologies Receives Grant from Juvenile Diabetes Research Foundation International for DIABECELL NZ Clinical Trial - US$500,000 towards current New Zealand Phase II Clinical Trial of DIABECELL

Clavis Pharma recruits first patient in pivotal Phase III study of elacytarabine in late-stage acute myeloid leukaemia - Clinical trial aims to confirm significant survival benefit seen in Phase II

Novartis to sell stake in consumer healthcare joint venture to GSK - Focussing on strategic priorities

1.5 million USD in new funding & new chairman of the board to iSentio AS

QIAGEN and Bayer HealthCare partner to develop companion diagnostics to guide treatment decisions for targeted cancer therapies

Novocure Announces Appointment of Wilco Groenhuysen as Chief Financial Officer

Clavis Pharma's CP-4126 Enters New Phase II Clinical Trial in Pancreatic Cancer Patients Refractory to 1st line Gemcitabine Therapy

Navamedic's glucosamine HCl product approved in 19 European countries for treatment of osteoarthritis

Bayer and Zydus Cadila sign Joint Venture Agreement to strengthen pharmaceutical business in India

Promising interim results of Phase II trial with elacytarabine in combination with idarubicin in patients with early stage acute myeloid leukaemia (AML)

Clavis Pharma announces negative outcome of pivotal LEAP Trial with CP-4126 in Patients with Metastatic Pancreatic Cancer

The Netherlands Cancer Institute (NKI) and to-BBB to collaborate on brain delivery of anti-cancer drugs